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Vascular calcification is one of the mechanisms mediating the
higher mortality risk associated with the hyperphosphatemia
of chronic kidney disease. Though common, and often severe
in non-dialyzed proteinuric diabetics, there are no studies
on the prognostic significance of coronary artery calcification
in early stage type 2 diabetic nephropathy. Here we deter-
mine this significance in 225 proteinuric diabetic patients
(mean age 57 years, mean estimated glomerular filtration rate
(eGFR) 52ml/min per 1.73m2 and a median urine
protein–creatinine ratio of 2.7). Coronary artery calcification,
measured by electron beam computed tomography, was
diagnosed in 86% of the patients, the severity of which
correlated with older age, male gender, and white ethnicity.
However, no association was found between eGFR, serum
calcium, phosphorus, parathyroid hormone, or 25-hydroxy
vitamin D. Over an average follow-up of 39 months, 54
patients died. A graded relationship between the severity
of calcification and all-cause mortality was consistently
demonstrated on both univariate and multivariate analyses.
Patients in the highest quartile of calcification score had a
2.5-fold higher risk for death. Our results show the severity of
coronary artery calcification early in the course of chronic
kidney disease is an independent predictor of all-cause
mortality. Additional studies need to determine whether
altering the natural history of coronary artery calcification
in early chronic kidney disease prolongs survival.
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published online 17 March 2010
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Patients with chronic kidney disease (CKD), including those
undergoing maintenance dialysis, suffer considerable mor-
bidity and mortality.1,2 Recent studies provide strong
evidence for the role of disordered mineral metabolism,
particularly elevated serum phosphorus levels, in explaining
some of the substantial increase in cardiovascular risk.3 In
concert with this accumulating epidemiological data, a large
body of cell culture and animal experiments has demon-
strated the key role of phosphorus in inducing vascular
calcification.4,5 These emerging data support the thesis that
the prevalence and severity of vascular calcification may be an
appropriate intermediate outcome measure for observational
and interventional studies in patients with CKD. Several
studies have shown that vascular calcification begins early
and is often severe during the course of CKD, particularly in
those with diabetes mellitus.6 Even though three randomized
controlled trials have shown an attenuation of progression of
vascular calcification with the use of non-calcium based
binder sevelamer hydrochloride in CKD subjects, the effect
of calcium avoidance on mortality of dialysis patients is
contradictory.7–11 It is conceivable that these apparently
disparate findings suggest that there may be an advantage to
begin intervention earlier in the course of CKD. However,
to our knowledge, the association between coronary artery
calcification (CAC) and mortality has heretofore not been
studied in non-dialysis-dependent CKD subjects—a necessary
prelude to any interventional studies that seek to use vascular
calcification as an intermediate outcome. We undertook this
study to test the hypothesis that a greater severity of CAC is
associated with a higher risk for all-cause mortality in non-
dialysis-dependent diabetic patients with overt proteinuria.
RESULTS
Subject characteristics and baseline CAC
The study cohort consisted of 225 proteinuric individuals
with type 2 diabetes and presumed diabetic nephropathy
(see Materials and Methods for definition). The baseline
characteristics of study population are summarized in Table 1.
CAC was present in 86% of study participants. Individuals in
the lowest quartile of CAC score were younger and had lower
serum 25-hydroxy vitamin D levels and non-Latino whites
were more likely to be in the higher quartiles; there was no
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significant difference between any of the other variables
among the four groups (Table 1). Specifically, there was no
significant difference in estimated glomerular filtration rate
(eGFR, Figure 1a), or stage of CKD (Figure 1b) among the
four quartiles of CAC scores. Furthermore, there was no
correlation of measures of mineral metabolism with the
severity of CAC scores (Spearman’s correlation coefficients
for the association of CAC with serum calcium, 0.02 (P¼ 0.83);
phosphorus, 0.03 (P¼ 0.71); parathyroid hormone (PTH),
0.07 (P¼ 0.37); and 25-hydroxy vitamin D, 0.07 (P¼ 0.37)).
Using multivariate linear regression analysis, increasing age
(P¼ 0.001), male gender (P¼ 0.01), and non-Latino whites
(P¼ 0.003) were independently associated with a higher log-
transformed baseline CAC score.
Baseline CAC and all-cause mortality
Deaths were ascertained either by contact with next of kin
and/or a screen of the National Death Index (NDI, available
through 31 December 2007). Over a mean observation period
of 39±25 months, 54 deaths occurred, yielding a crude
mortality rate of 5.7 per 100 patient years for the cohort. Of
the 54 deaths, 40 occurred on or before 31 December 2007—
29 were identified on both the NDI search and contact with
next of kin, 5 were identified on NDI data screen, and 6 were
Table 1 | Baseline patient characteristics, stratified by quartile of coronary artery calcification score
1st Quartile
(0–15)
2nd Quartile
(16–149)
3rd Quartile
(150–427)
4th Quartile
(X428) P-value Entire cohort
Sample size (n) 56 57 56 56 225
Demographics
Age (years) 54±7 58±8 58±7 58±6 0.009 57±7
Gender (% males) 45 47 64 61 0.09 54
Race/ethnicity (n (%)) 0.03a
Non-Latino whites 3 (5) 2 (4) 10 (18) 11 (20) 26 (12)
Non-Latino blacks 15 (27) 11 (19) 8 (14) 10 (18) 44 (20)
Latino 38 (68) 41 (72) 37 (66) 34 (61) 150 (67)
Others 0 (0) 3 (4) 1 (2) 1 (2) 5 (2)
Clinical characteristics
DM duration (years) 15±5 16±7 15±7 16±7 0.71 16±6
History of CV disease (n (%)) 12 (21) 16 (28) 16 (29) 22 (39) 0.19 66 (29)
Current smoker (n (%)) 8 (14) 8 (14) 11 (20) 12 (21) 0.65 39 (17)
Body mass index (kg/m2
b
) 28 (6) 31 (12) 29 (11) 30 (10) 0.35 29 (10)
Systolic BP (mmHg) 152±28 157±27 159±27 157±30 0.56 156±28
Diastolic BP (mmHg) 76±12 76±12 79±14 78±14 0.62 77±13
Laboratory data
Serum creatinine (mg/dl) 1.5 (0.8) 1.3 (1.2) 1.4 (1.0) 1.6 (1.0) 0.55 1.5 (1.0)
eGFR (ml/min per 1.73m2) 51±25 54±28 53±26 49±34 0.75 52±26
HbA1c (%) 8.6±2.4 8.4±2.4 8.5±2.1 8.3±2.1 0.88 8.4±2.2
Total cholesterol (mg/dl) 207 (95) 189 (64) 178 (59) 190 (73) 0.14 189 (69)
LDL-cholesterol (mg/dl) 109 (64) 112 (52) 102 (48) 113 (61) 0.47 109 (59)
Corrected serum calcium (mg/dl) 9.7±0.5 9.8±0.4 9.7±0.4 9.8±0.4 0.99 9.7±0.4
Serum phosphorus (mg/dlb) 4.5 (0.8) 4.2 (0.8) 4.3 (1.0) 4.4 (0.9) 0.39 4.3 (1.0)
Serum parathyroid hormone (pg/mlb) 62 (69) 55 (96) 45 (52) 56 (84) 0.49 55 (68)
Serum 25-hydroxy vitamin D (ng/ml) 16 (12) 24 (18) 24 (14) 23 (15) 0.009 23 (14)
C-reactive protein (40.4mg/l, n (%)) 21 (38) 33 (58) 29 (52) 28 (50) 0.21 111 (50)
Serum albumin (g/dl) 3.1±0.5 3.3±0.6 3.3±0.5 3.2±0.6 0.11 3.2±0.6
Urine protein–creatinine ratio (mg/mgb) 3.2 (4.7) 2.3 (3.3) 2.2 (3.1) 3.3 (6.2) 0.43 2.7 (4.7)
Baseline medical therapyc
ACEIs or ARBs (n (%)) 38 (68) 48 (84) 46 (82) 40 (71) 0.04 172 (76)
b Blocker (n (%)) 23 (41) 26 (46) 30 (54) 35 (63) 0.11 114 (51)
Total number of anti-hypertensive agentsb 2 (1) 2 (2) 2 (2) 2 (2) 0.32 2 (2)
Aspirin (n (%)) 23 (41) 29 (51) 23 (41) 27 (48) 0.82 102 (45)
Lipid-lowering agents (n (%)) 34 (61) 29 (51) 38 (68) 37 (66) 0.10 138 (61)
Phosphate binders (n (%)) 1 (2) 3 (5) 1 (2) 2 (4) 0.71 7 (3)
Active vitamin D (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
CAC scorea,b 0 (3) 73 (66) 257 (153) 1112 (1020) 149 (415)
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blockers; BP, blood pressure; CAC, coronary artery calcification; CV, cardiovascular;
DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Data expressed as means±s.d., except where indicated.
aOthers not used to calculate significance of difference of proportions in each quartile.
bData expressed as median and interquartile range.
cThe data on medications were missing for 10 subjects.
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identified by contact with next of kin only (predominantly
because of death occurring outside the United States
of America). All the deaths after 31 December 2007
(n¼ 14) were ascertained by contact with next of kin. There
was a graded increase in the unadjusted risk for death with
higher quartiles of CAC score (Table 2, and Figure 2;
univariate log-rank sum test P-value, 0.015).
In addition to the baseline CAC score, race/ethnicity,
estimated GFR, and serum albumin were significantly associated
with a higher risk of death on univariate Cox’s proportional
hazards analysis (Table 3). The trend for an association of urine
protein–creatinine ratio, and the use of b blockers with mortality
did not reach statistical significance (Table 3).
Higher CAC score was an independent predictor of all-
cause mortality in each one of the three multivariate models
tested (data adjusted for race/ethnicity, estimated GFR,
serum albumin, urine protein–creatinine ratio, and the use
of b blockers)—in the first multivariate model, log10(CAC
scoreþ 1) was used as a continuous variable; in the second,
quartile of CAC score was entered as categorical variables;
and in the third, pre-determined cut-off ranges of CAC score
were used (0, 1–99, 100–399, andX400) (Table 4). Additional
adjustment of data for age and gender did not change the
hazard ratio for death with higher CAC scores in any of the
three models.
Sensitivity analyses
Of the 171 subjects whose follow-up was censored, the last
date of contact by the study staff for 21 participants occurred
before the last day for which data were available from the
NDI (31 December 2007). In order to exclude bias
introduced by the censoring strategy, analyses were repeated
such that follow-up was censored either at the time of death
or last contact by study staff. In this sensitivity analysis, the
mean observation period was 36±24 months. Using the log-
rank sum test, increasing quartiles of CAC score were
significantly associated with a higher risk for death on
univariate analyses (P¼ 0.018). The same additional uni-
variate predictors of all-cause mortality were identified (race/
ethnicity, estimated GFR, and serum albumin). Baseline CAC
score remained an independent predictor of all-cause
mortality in each one of the three multivariate models tested
(hazard ratios for CAC score variable in model 1, P¼ 0.005;
model 2, P¼ 0.005; and model 3, P¼ 0.01).
DISCUSSION
To our knowledge, this study is the first to report a significant
association between CAC score obtained early in the course
of CKD (baseline eGFR 52ml/min per 1.73m2) and
subsequent risk for death upon follow-up for a little over 3
years. Furthermore, this is the largest study that has evaluated
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Figure 1 |Association of the severity of coronary artery
calcification (CAC) with renal function. Proportions of patients
in each quartile of CAC score, stratified either by (a) quartile of
estimated glomerular filtration rate (eGFR), or (b) stage of chronic
kidney disease. The ranges of eGFR in each quartile of GFR were:
1st quartile,p31; 2nd quartile, 32–47; 3rd quartile, 47–71; and 4th
quartile, X71ml/min per 1.73m2.
Table 2 | Unadjusted mortality rate, stratified by quartile of coronary artery calcification (CAC) score
1st Quartile 2nd Quartile 3rd Quartile 4th Quartile P-value Entire cohort
CAC score range 0–15 16–149 150–427 X428
Number of subjects 56 57 56 56 225
Observation period, months 42±23 43±27 37±25 34±25 39±25
Death (n (%)) 10 (18) 10 (18) 13 (23) 21 (38) 54 (24)
Unadjusted mortality rate per 100 patient years 5.1 5.0 7.5 13.9 0.015 5.7
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CAC in non-dialysis-dependent CKD subjects, and in this
population enriched with individuals with substantial under-
lying renal disease and a near-universal prevalence of vascular
calcification, we were unable to demonstrate a significant
association between either eGFR or measures of mineral
metabolism with the severity of CAC.
It has now long been known that maintenance dialysis
patients have a very high burden of vascular calcification such
that the CAC scores on electron beam computed tomography
are substantially and markedly higher than age- and gender-
matched controls.12,13 Furthermore, the presence and/or severity
of vascular calcification—whether ascertained by plain radio-
graphy, ultrasonography, or on computed tomography—has
been shown to be associated with all-cause and cardio-
vascular mortality in patients undergoing maintenance
dialysis.11,14–16 The CAC scores reported in studies of subjects
with non-dialysis-dependent CKD are substantially lower than
those observed in populations of dialysis patients (reviewed
by Mehrotra6). However, both the prevalence and severity of
calcification in subjects with early-stage diabetic CKD, are
significantly higher than in age- and gender-matched control
diabetics and non-diabetics without kidney disease.17,18 This is
illustrated in our relatively large population of proteinuric
diabetics, 86% of who had demonstrable coronary calcifica-
tion and in more than one-quarter of patients, it exceeded
400 (severe calcification). It is now well-recognized that
‘calcification begets calcification’; thus, the severity of
calcification during early stages of CKD identifies those
individuals, if alive by the time the disease reaches end-stage
renal disease, who will have the greatest increase in
systemic vascular calcification burden.19–21 This is further
highlighted by the demonstration of a consistent, and
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Figure 2 |Kaplan–Meier survival curve for all-cause mortality
in the cohort, stratified by the quartile of coronary artery
calcification (CAC) score. The P-values for the trend to predict
all-cause mortality with quartile of CAC score were 0.02 by
univariate and 0.005 by multivariate Cox proportional hazards
model.
Table 3 | Summary of baseline predictors of mortality on
univariate analyses using the Cox proportional hazards
model with P-value o0.10
Variable
Hazard ratio
(95%CI) P-value
CAC score (ref.: 1st quartile: 0–15) 0.02
2nd quartile (16–149) 0.97 (0.40, 2.33)
3rd quartile (150–427) 1.46 (0.64, 3.34)
4th quartile (X428) 2.61 (1.23, 5.54)
Race/ethnicity (ref.: Latino) 0.003
Non-Latino whites 3.06 (1.41, 6.62)
Non-Latino blacks 2.63 (1.45, 4.78)
Others —
eGFR (ref.: 1st quartile: p31.0ml/min per 1.73m2) 0.004
2nd quartile (32.0–46.9ml/min per 1.73m2) 0.78 (0.41, 1.49)
3rd quartile (47.0–70.7ml/min per 1.73m2) 0.39 (0.18, 0.83)
4th quartile (X70.8ml/min per 1.73m2) 0.19 (0.07, 0.56)
Serum albumin (ref.: 1st quartile: p2.9 g/dl) 0.004
2nd quartile (3.0–3.2 g/dl) 0.62 (0.32, 1.08)
3rd quartile (3.3–3.5 g/dl) 0.41 (0.19, 0.88)
4th quartile (X3.6 g/dl) 0.24 (0.10, 0.56)
Urine protein–creatinine ratio (ref.: 1st quartile, p1.23mg/mg) 0.053
2nd quartile (1.24–2.658mg/mg) 1.20 (0.45, 3.15)
3rd quartile (2.659–5.86mg/mg) 1.06 (0.40, 2.86)
4th quartile (X5.87mg/mg) 2.58 (1.09, 6.08)
Missinga 1.76 (0.41, 3.47)
Use of b-blocker, (ref.: no) 0.08
Yes 1.92 (1.09, 3.39)
Missing 1.90 (0.43, 8.03)
Abbreviations: CAC, coronary artery calcification; CI, confidence interval; eGFR,
estimated glomerular filtration rate.
aOf 11 participants categorized as ‘missing’, data on 24-h urine protein excretion
(without simultaneous measurement of creatinine) were available and used to
determine eligibility for 7, and for 4 subjects, eligibility was determined at another
hospital and data are not currently available.
Table 4 | Summary results of different multivariate analyses
for the hazards ratio for death with CAC score
Predictors
Hazard ratio
(95%CI) P-value
Model 1a
Log10 (CAC score+1), for every 1 increase 1.59 (1.17, 2.18) 0.004
Model 2a
CAC score (ref.: 1st quartile) 0.005
2nd quartile 1.33 (0.54, 3.22)
3rd quartile 1.41 (0.67, 3.61)
4th quartile 3.54 (1.61, 7.77)
Model 3a
CAC score (ref.: score 0) 0.01
1–99 1.49 (0.42, 5.26)
100–399 2.20 (0.63, 7.72)
X400 4.32 (1.26, 14.78)
Abbreviations: CAC, coronary artery calcification; CI, confidence interval.
aAdjusted for race/ethnicity, estimated glomerular filtration rate (eGFR), serum
albumin, urine protein–creatinine ratio, and use of b-blockers.
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independent-graded relationship between CAC score at an
average eGFR of 52ml/min per 1.73m2, and all-cause
mortality in this study. Our findings are consistent with a
recent study of 117 non-dialysis-dependent CKD subjects in
whom a significant, univariate association of CAC with
mortality (n¼ 4), cardiovascular events (n¼ 15), and hospi-
talization (n¼ 19) was observed. However, in that study the
small number of events allowed for only limited multivariate
adjustment and the authors were unable to confirm the
independent association of CAC score with mortality.22 Our
findings are robust as they are based on a significant number
of events (deaths, 54) over a relatively long period of follow-
up (mean, 39 months). Furthermore, the higher risk for
death with increasing CAC score was consistently seen in each
one of the three a priori specified multivariate models
(Table 4).
Vascular calcification can occur in either the intima
(calcified atherosclerotic plaques), or the media of the blood
vessels; the prevalence and severity of both intimal and
medial calcification is increased with CKD.23,24 Furthermore,
plausible explanations have been put forth to explain how
either intimal or medial calcification may lead to greater
morbidity and mortality. Thus, the severity of intimal
calcification is associated with coronary atherosclerosis and,
possibly with ischemic cardiac damage.25 On the other hand,
medial calcification is associated with vascular stiffness,
increased cardiac after-load, left ventricular hypertrophy, and
congestive heart failure.4 Limited evidence suggests that most
of the calcification seen in the coronary artery is located in
the intima, but electron beam computed tomography cannot
distinguish intimal from medial calcification.24,26 Moreover,
we did not measure either the myocardial perfusion or
vascular stiffness, or ventricular function and are unable to
determine the mechanisms to explain the association of
CAC score with all-cause mortality. Nevertheless, the effect
size of increasing severity of vascular calcification was rather
large such that subjects in the highest quartile of CAC score
(X428) had a 2.5-fold higher risk for mortality (ref., lowest
quartile, CAC score 0–15). Analyzing the data differently,
those with severe CAC (score X400) had a 3.3-fold higher
risk for death when compared with those with no detectable
calcification (score 0). However, notwithstanding the clear
trend of higher hazards ratio with increasing CAC scores, the
risk for death was significantly higher only in individuals in
the highest category of CAC score. This may be secondary to
smaller number of events in the categories of lower CAC, or
this may suggest that there is a threshold effect whereby the
risk increases only when the CAC score exceeds about 400 U.
Even though our data only demonstrate an association and
not a causal relationship, it makes a strong argument to
understand some of the pathophysiological mechanisms
involved in the induction and progression of vascular
calcification in early CKD. Understanding these mechanisms
may provide us with insights into potential therapeutic
interventions that may retard the progression of calcification
and have a salutary effect on mortality.
As has been reported by others, increasing age, male
gender, and non-Latino white race were associated with a
greater severity of CAC.27–29 We have previously demon-
strated that compared with diabetes duration-matched
normoalbuminuric controls, subjects with diabetic nephro-
pathy have a significantly higher prevalence and greater
severity of CAC.18 Thus, the severity of vascular calcification
burden in our study cohort reflects the effects of both
diabetes mellitus and CKD. However, unlike some recent
studies, we were unable to demonstrate an association
between eGFR with either the prevalence or severity of
CAC.30,31 These apparently discordant findings should be
interpreted with caution—the data on proteinuria were not
available in most of the studies that have demonstrated
an inverse association between eGFR and CAC scores. In
contrast, overt proteinuria was a pre-requisite for enrollment
in our study cohort. Furthermore, our study was limited only
to subjects with type 2 diabetes, and should be extrapolated
to non-diabetics with caution. This issue deserves further
study using diabetic and non-diabetic cohorts with a wider
range of urine protein excretion (from normoalbuminuria to
overt proteinuria).
Similarly, unlike some recent studies, we were unable
to demonstrate an association between any measure of
mineral metabolism (serum calcium, phosphorus, PTH, and
25-hydroxy vitamin D levels) with the severity of CAC. The
lack of association of the severity of vascular calcification
with serum P was somewhat surprising as some recent studies
have shown an association between serum phosphorus levels
and incident and prevalent vascular calcification in indivi-
duals with and without CKD.31–35 There is strong evidence
from cell culture and animal experiments that supports the
notion that phosphorus is very important in the induction
and progression of vascular calcification.4–5,36 However,
serum phosphorus accounts for o1% of the total body
phosphorus content and thus, may not be an accurate
reflection of the total systemic phosphorus burden. Even
though a higher ‘phosphorus burden’ is thought to underlie
the increase in serum fibroblast growth factor-23 and PTH
levels seen rather early during the course of CKD, neither
post-absorptive nor post-prandial hyperphosphatemia are
demonstrable until GFR declines to o30ml/min per
1.73m2.37,38 Furthermore, the association of serum fibroblast
growth factor-23 levels with risk for death and the survival
advantage with the use of phosphate binders in incident
dialysis patients is independent of serum phosphorus
levels;39,40 this possibly also highlights the limitation of
serum phosphorus as a marker of systemic phosphorus
exposure. Consistent with these arguments, many previous
studies have been unable to demonstrate any association
between serum phosphorus levels and the severity of vascular
calcification in either dialysis or non-dialysis CKD sub-
jects.12,14,18,41–49 Moreover, even though an association
between serum phosphorus and the prevalence of vascular
calcification was seen at baseline among participants in
the Multi-Ethnic Study of Atherosclerosis, there was no
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demonstrable association between serum phosphorus and the
progression of CAC.19,32 In addition to the limitation of the
serum phosphorus level as a marker of systemic phosphorus
exposure, there may be other reasons to explain this lack of
association in our study. As pointed out earlier, our cohort
had significant renal disease and the mean serum phosphorus
levels were significantly higher than in many other previous
studies. This may be secondary to tubular dysfunction from
diabetic kidney disease that is not captured in the measure-
ment of eGFR and/or a higher dietary phosphorus intake in
our largely Latino population.
Use of the non-calcium phosphate binder, sevelamer
hydrochloride, has been shown to attenuate the rate of
progression of calcification in non-dialysis dependent CKD
subjects.9 Thus, it appears possible to modify the natural
history of progression of calcification. However, virtually
none of our patients were being treated with calcium or non-
calcium phosphate binders at the time of initial evaluation.
Furthermore, the effect of slowing the rate of progression
of vascular calcification on the subsequent risk for death in
non-dialysis-dependent CKD subjects is presently not known
and needs to be further investigated.
Despite its considerable strength and novel findings, our
study is not without limitations. First, our study was limited
to proteinuric diabetics and the study participants were
predominantly Latinos. Hence, extrapolation of our study
results to non-diabetics or other racial populations should be
done with caution. Furthermore, the association of urine
protein excretion with mortality in our study cohort did not
reach statistical significance. This may be a result of having
included only individuals with overt proteinuria in our study
cohort and as discussed earlier, the association needs to be re-
examined in cohorts with a wider range of urine protein
excretion. Second, ascertainment of risk factors was done
only at baseline visit; those subjects who are still alive, are
being periodically re-evaluated and thus, we will be able to
evaluate the effect of change in risk factor profile over time
on mortality in the future. Furthermore, our inability to
demonstrate an association between the use of different
classes of medications (like angiotensin-converting enzyme
inhibitors, angiotensin-receptor blockers, and statins) and
mortality may be secondary to several reasons—their use was
also ascertained only at baseline visit, and the adherence with
the therapy or duration of use was not ascertained after the
baseline visit. Third, concern has been raised that the NDI
may not provide reliable information on the death of Latinos,
as many of the sick and infirm may return to the country of
their origin (‘salmon effect’);50 to avoid bias arising from this,
we carried out a sensitivity analysis by using an alternative
method of censoring which yielded the same result. Fourth,
the abbreviated four-variable Modification of Diet in Renal
Disease equation used to estimate the glomerular filtration
rate is not validated in Latino population—the predominant
group in our study cohort. Finally, we did not have the
information to analyze the association with cause-specific
mortality.
To conclude, this is the first study to demonstrate a graded
and consistent association between the severity of CAC early
during the course of CKD with the risk for death. Future
studies need to determine if altering the natural history
of vascular calcification in early CKD will translate into a
reduction in mortality in this high-risk population.
MATERIALS AND METHODS
Study subjects and baseline assessment
This is an analysis that pools participants from two prospective
cohort studies of CAC in non-dialysis-dependent type 2 diabetics
with nephropathy. The primary aim of each of the two studies was
to evaluate racial/ethnic differences in prevalence and severity of
CAC and some of the data from these two studies has been
published previously.18,51 The criteria used to define type 2 diabetes
and diabetic nephropathy were similar in both studies and represented
a modification from the National Institute of Diabetes and Digestive
and Kidney Diseases-sponsored Family Investigation of Nephropathy
in Diabetes study:52 diagnosis of diabetes mellitus after the age
of 30 years and treatment with either diet or oral hypoglycemic
agents for at least 6 months, neither current nor previous treatment
with maintenance dialysis or renal transplantation, urine protein–-
creatinine ratioX0.5mg/mg either at the time of enrollment or at least
once in the preceding 12 months before enrollment and one of the
following two criteria (1) diabetes durationX10 years (or in individuals
with retinopathy, X5 years), and/or (2) renal biopsy evidence of
diabetic nephropathy. The study was approved by the Institutional
Review Board at Los Angeles Biomedical Research Institute.
All study participants were scheduled for an outpatient clinic
visit at the General Clinical Research Center. The subjects were asked
to come in after an overnight fast and bring all the prescribed
medications on the day of the study. Study procedures included
relevant medical history, measurement of height and weight,
recording blood pressure in duplicate, and collection of urine and
blood samples. Data thus collected were used to determine the
prevalence and/or severity of traditional (age, gender, hypertension,
dyslipidemia, current smoking, obesity, and C-reactive protein), renal-
related (urine protein–creatinine ratio, serum creatinine, albumin,
calcium, phosphorus, intact PTH, and 25-hydroxy vitamin D)
and diabetes-related (glycosylated hemoglobin (HbA1c) and dura-
tion of type 2 diabetes mellitus) risk factors. Clinical evidence of
cardiovascular disease was defined as the presence of one of the
following: angina on the Rose questionnaire, or history of either
myocardial infarction, or previous revascularization, or cerebro-
vascular accident. Intact PTH concentrations were measured using
immunochemiluminometric assay (Quest Diagnostic Nichols
Institute, San Juan Capistrano, CA, USA; reference range 10–65pg/ml),
25-hydroxy vitamin D levels using liquid chromatography, tandem
mass spectroscopy (Quest Diagnostic Laboratory, San Juan Capistrano,
CA, USA; analytic sensitivity 4 ng/ml), and albumin was measured
using bromocresol purple method. GFR was estimated using the
abbreviated four-variable Modification of Diet in Renal Disease
equation.53 Electron beam computed tomography scan was used to
determine the CAC score on the day of the clinic visit, as reported
previously.18 The scans were read by experienced readers who were
blind to the clinical information of the study participants.
Subject follow-up and ascertainment of outcomes
As per the study protocol, subjects and/or their next of kin were
contacted by telephone at 6-month intervals to ascertain the vital
status of each participant. If telephone contact was unsuccessful,
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at least two certified letters were sent to the subject at their last
known address, followed by a home visit by one of the members of
the study staff. The information obtained from direct subject
contact was supplemented by a screen of the NDI up until the last
available data (through 31 December 2007). For a subject whose
death could not be confirmed by direct contact with next of kin,
probabilistic scores provided by the NDI were used to identify study
participants as deceased. Subjects were followed up till either date of
death, or last telephone contact, or 31 December 2007 (last date for
which data are available from the NDI), whichever occurred later.
Statistical analysis
Continuous variables are expressed as mean and s.d., or median
with inter-quartile range, as appropriate, and categorical variables as
percentages. The significance of difference between continuous
variables was tested using either t-test, one-way analysis of variance,
Mann–Whitney rank-sum test, or Kruskal–Wallis test, as appro-
priate. The difference in the distribution of categorical variables was
tested using the w2-test. Correlations were tested using Spearman’s
rank-sum test.
Time-to-event survival analysis was used to test the association
between the baseline CAC score and all-cause mortality. Univariate
and multivariate predictors of time-to-event were identified using
Cox’s proportional hazards model. In addition to the baseline
CAC score, univariate associations with mortality were tested with
the following variables: age, gender, race/ethnicity, current smoking,
history of cardiovascular disease, duration of diabetes, body
mass index, systolic and diastolic blood pressure, lipid profile,
HbA1c, eGFR, corrected serum calcium, phosphorus, intact PTH,
25-hydroxy vitamin D, albumin, C-reactive and urine protein–creatinine
ratio, use of aspirin, angiotensin-converting enzyme inhibitor
and/or angiotensin-receptor blocker, b blocker, lipid-lowering agent,
and a number of anti-hypertensive agents. All continuous variables
were categorized into quartiles; a fifth category of missing data was
created for variables, if indicated. All predictors with a P-value of
o0.10 on univariate analyses were entered into the multivariate
models. In order to determine the independent predictive value of
baseline CAC score, three multivariate models (selected a priori)
were built—log-transformed CAC score as continuous variable,
and either quartiles of CAC score (0–15, 16–149, 150–427, and
X428) or categories based on pre-defined ranges of CAC score
(0, 1–99, 100–399, and X400) as categorical variables.54
Sensitivity analysis was carried out using an alternative censoring
method such that length of follow-up was calculated as either up
until time of death or last phone or in-person contact by study staff.
PASW Statistics 17.0 software (SPSS, Chicago, IL, USA) was
used for all the statistic analyses above. A P-value of o0.05 was
considered statistically significant.
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